Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

Autor: Salvador Bofill, Javier, Moreno Anton, Fernando, Rodriguez Sanchez, Cesar Augusto, Galve Calvo, Elena, Hernando Melia, Cristina, Ciruelos Gil, Eva Maria, Vidal, Maria, Jiménez-Rodriguez, Begoña, De la Cruz Merino, Luis, Martínez Jañez, Noelia, Villanueva Vazquez, Rafael, de Toro Salas, Ruben, Anton Torres, Antonio, Alvarez Lopez, Isabel Manuela, Gavila Gregori, Joaquin, Quiroga Garcia, Vanesa, Vicente Rubio, Elena, De la Haba-Rodriguez, Juan, Gonzalez-Santiago, Santiago, Diaz Fernandez, Nieves, Barnadas Molins, Agusti, Cantos Sanchez de Ibargüen, Blanca, Delgado Mingorance, Juan Ignacio, Bellet Ezquerra, Meritxell, de Casa, Sonia, Gimeno, Asuncion, Martin, Miguel
Zdroj: In The Breast December 2022 66:77-84
Databáze: ScienceDirect
Externí odkaz: